06/03/2026
The conversation around Signatera is growing within the IBC community, but many patients still have questions about what the test can—and cannot—tell us.
As Dr. Wendy Woodward and Dr. Azadeh Nasrazadani explained during a recent Talk IBC discussion, circulating tumor DNA testing holds tremendous promise, but researchers are still working to understand how best to use the information it provides.
One takeaway stood out:
"The test may provide data. But data and answers are not always the same thing."
Read our latest blog post to learn what IBC patients need to know about Signatera, why doctors may approach it differently, and why there is still so much reason for hope.
The conversation around Signatera is growing within the IBC community, but many patients still have questions about what the test can—and cannot—tell us. Researchers are still working to understand how best to use the information it provides.